ERBB2 and breast carcinoma: Herceptin (trastuzumab) is a humanised monoclonal antibody that specifically targets HER2 (EGFR-2/ERBB2) (Walshe et al., 2006), which is overexpressed in approximately 20% of breast cancers (Baselga et al., 1998).